Ji-Chuan decoction ameliorates slow transit constipation via regulation of intestinal glial cell apoptosis

作     者：Xiu-Min Wang Li-Xia Lv Yue-Si Qin Yu-Zhu Zhang Ni Yang Shu Wu Xiu-Wen Xia Hong Yang Hong Xu Ying Liu Wei-Jun Ding 

作者机构：Department of Fundamental MedicineChengdu University of Traditional Chinese MedicineChengdu 610072Sichuan ProvinceChina Department of ProctologyChengdu First People’s HospitalChengdu 610041Sichuan ProvinceChina Department of Endocrinology and MetabolismChengdu First People’s HospitalChengdu 610041Sichuan ProvinceChina Department of DermatologyChengdu First People’s HospitalChengdu 610041Sichuan ProvinceChina Department of Preventive MedicineShantou University Medical CollegeShantou 515063Guangdong ProvinceChina 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2022年第28卷第34期

页      面：5007-5022页

核心收录：

学科分类：1008[医学-中药学(可授医学、理学学位)] 1006[医学-中西医结合] 100602[医学-中西医结合临床] 10[医学] 

基　　金：Supported by the National Natural Science Foundation of China,No. 82074151 the Experimental Formulary Sichuan Youth Science and Technology Innovation Research Team,No. 2020JDTD0022 

主　　题：Slow-transit constipation Ji-Chuan decoction Taurine and hypotaurine metabolism AKT Enteric glial cell Apoptosis 

摘      要：BACKGROUND Slow transit constipation(STC)is a common intestinal disease with increasing *** results from various factors,such as the enteric nervous system and metabolic *** a classical formula of traditional Chinese medicine,Ji-Chuan decoction(JCD)has been extensively and effectively used in STC treatment,yet its pharmacological mechanism remains *** To explore the integrated regulatory pattern of JCD against STC through hyphenated techniques from metabolism,network pharmacology and molecular *** STC model mice were generated by intragastric administration of compound diphenoxylate(10 mg/kg/d)for 14 *** STC mice in the low dose of JCD(3.04 g/kg),middle dose of JCD(6.08 g/kg)and high dose of JCD(12.16 g/kg)groups were orally administered JCD solution once a day for 2 *** acetylcholine(ACH)level was examined by enzyme-linked immunosorbent *** pathological features of colon tissue were observed by hematoxylin and eosin *** differentially expressed metabolites and metabolic pathways were tested by nontargeted *** main targets and core ingredients of JCD were identified by network pharmacology,and the expression of AKT was confirmed by ***,the pathways involved in JCD treatment were predicted using a combination of differentially expressed metabolites and targets,and intestinal glial cell apoptosis was demonstrated by *** JCD significantly promoted intestinal motility,increased the levels of the excitatory neurotransmitter ACH and reduced intestinal inflammation in STC *** metabolomics results showed that JCD significantly restored metabolic dysfunction and significantly affected taurine and hypotaurine *** pharmacology and molecular experiments showed that JCD regulates AKT protein expression,and the core component is *** analysis demonstrated that apoptosis may be an important mechanism by which JCD relieves co